One-sentence summary of key findings: Mesoblast (MESO) is an Australian biotech company pioneering allogeneic mesenchymal lineage cell therapies, with its first FDA-approved product Ryoncil now generating meaningful revenue (e.g., US$36M in Q4 FY2026) while advancing pivotal Phase 3 trials for chronic low back pain and other indications, supported by strong analyst price targets indicating significant upside potential from current levels around $18.
Fact: As of the most recent market data (morning of July 15, 2026), MESO traded at approximately $18.10 - $18.18 (up ~8% intraday from previous close of $16.74), with a market capitalization of ~$2.12B - $2.34B. View live quote on Yahoo Finance
Data limitation: Stock prices are highly volatile and real-time; this snapshot is from tool crawl during market hours and does not constitute investment advice. Always verify current price.
| Metric | Value |
|---|---|
| 52-Week Range | $11.05 - $21.50 |
| YTD Return | ~0.31% |
| 1-Year Return | ~65.11% |
| 3-Year Return | ~88.50% |
| 5-Year Return | ~22.27% |
| Beta (5Y Monthly) | 0.80 |
| Avg. Volume (3M) | 188,072 |
Full performance chart and historical data on Yahoo Finance
| Metric | Value | Source/Notes |
|---|---|---|
| Revenue (TTM) | $65.38M | Yahoo Finance; strong growth from Ryoncil launch (e.g., $36M net in Q4 ended June 2026) |
| Net Income (TTM) | -$94.37M | Yahoo Finance |
| EPS (TTM) | -$0.79 | Yahoo Finance |
| Profit Margin | -144.33% | Yahoo Finance |
| Total Cash (mrq) | $129.97M | Yahoo Finance |
| Total Debt (mrq) | $135.14M | Yahoo Finance; Debt/Equity 23.52% |
| Market Cap | ~$2.12B - $2.34B | Yahoo Finance |
| Employees | 81 | Company reports / IBISWorld |
| Fiscal Year End | Revenue |
|---|---|
| 6/30/2022 | 10.21 |
| 6/30/2023 | 7.5 |
| 6/30/2024 | 5.9 |
| 6/30/2025 | 17.2 |
| TTM (recent) | 65.38 |
Interpretation: Revenue acceleration in recent periods reflects initial commercialization of Ryoncil (remestemcel-L) following FDA approval for pediatric steroid-refractory acute graft-versus-host disease (SR-aGvHD).
Uncertainty: Sustained profitability remains distant; ongoing R&D expenses and clinical trial costs continue to drive losses.
Detailed financial statements on Yahoo Finance | Company Investor Relations
Fact: Analyst coverage is limited but generally positive on upside potential. Consensus price targets range from ~$12.50 to $35.00 across sources (e.g., $35.00 average on Yahoo with Strong Buy lean; $24.87 on Chartmill implying ~48% upside from ~$16.70; mixed Hold/Buy on MarketBeat).
| Source | Avg. Target | Implied Upside (from ~$16.70-$18) | Consensus |
|---|---|---|---|
| Yahoo Finance | $35.00 | ~94-110% | Strong Buy (recent Jefferies upgrade) |
| Chartmill | $24.87 | ~48% | Positive |
| Benzinga | $12.50 | Lower | Mixed (6 analysts) |
| MarketBeat | N/A (1 Sell, 1 Hold, 1 Strong Buy) | -- | Hold |
Interpretation: Targets suggest market sees substantial long-term value from pipeline (CLBP, heart failure) and commercial traction, though near-term volatility expected.
Uncertainty: Targets vary widely by analyst and date; limited coverage (few analysts) increases uncertainty. Ratings can change with trial data or regulatory news.
Fact: Mesoblast Limited (founded 2004 by Silviu Itescu, headquartered in Melbourne, Australia) develops regenerative medicines using proprietary mesenchymal lineage cell technology platform. It focuses on allogeneic (off-the-shelf) cell therapies for inflammatory diseases, cardiovascular conditions, and back pain. Key approved product: Ryoncil (remestemcel-L) for pediatric SR-aGvHD (FDA approved). Pipeline includes rexlemestrocel-L for chronic heart failure and chronic low back pain (Phase 3). Partnerships: Tasly (China), JCR (Japan), Grünenthal (Europe). Official website | Wikipedia overview
Interpretation: Transition from pure R&D to commercial stage marks a critical inflection point.
Uncertainty: Long-term success depends on additional regulatory approvals and market adoption in competitive cell therapy space.
Interpretation: B2B model with limited public customer disclosure; focus on global partnerships for commercialization.
Uncertainty: Actual end-user adoption rates post-approval not fully disclosed; reimbursement and physician uptake key variables.
| Company | Ticker | Focus Area | Notes |
|---|---|---|---|
| Cynata Therapeutics | CYP.AX | MSC therapies | Direct peer in allogeneic MSCs |
| Allogene Therapeutics | ALLO | Allogeneic CAR-T / cell therapies | Broader cell therapy platform |
| BrainStorm Cell Therapeutics | BCLI | Neurodegenerative / MSC | Similar MSC approach |
| SanBio | SBIO (Japan) | Regenerative medicine | Neurological focus |
| Lineage Cell Therapeutics | LCTX | Cell therapies | Broader regenerative |
Data limitation/assumption: Competitor list based on public searches; not exhaustive. Market dynamics in cell therapy evolve rapidly with new entrants and M&A.
Generated July 15, 2026. Sources primarily Yahoo Finance, company site, Wikipedia, and aggregated search results.